ArticleThe British journal of dermatology2019
Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa.
Article in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Dietary patterns in western patients with hidradenitis suppurativa: a cross-sectional study using the rapid prime diet quality screener.Scientific reports · 2026Article
- Surgical approaches in the management of hidradenitis suppurativa: Techniques, risks, and clinical outcomes.Dermatology online journal · 2026Review
- Presentations of Cutaneous Disease in Various Skin Pigmentations: Hidradenitis Suppurativa.HCA healthcare journal of medicine · 2026Article
- Article
- Clinical and laboratory characteristics of hidradenitis suppurativa in a Chinese cohort: a retrospective analysis of 197 cases.Frontiers in medicine · 2025Article
- The Impact of Diet on Hidradenitis Suppurativa Severity: A Cross-Sectional Case-Control Study.Medicina (Kaunas, Lithuania) · 2024Article
- Decades Delayed in Diagnosis: Hidradenitis Suppurativa and a Review of Barriers to Care.Cureus · 2024Article
- Unlocking the Mechanisms of Hidradenitis Suppurativa: Inflammation and miRNA Insights.Clinical, cosmetic and investigational dermatology · 2024Review
- Patients' Expectations and Satisfaction with the Patient-Doctor Relationship in Hidradenitis Suppurativa.Healthcare (Basel, Switzerland) · 2023Article
- The Relevant Oral Burden of Patients with Hidradenitis Suppurativa.Dermatology and therapy · 2023Article
- Satisfaction with Life and Coping Strategies among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study.Journal of clinical medicine · 2023Article
- Top applications of dermatologic ultrasonography that can modify management.Ultrasonography (Seoul, Korea) · 2023Article
- Potential Predictors of Cardiovascular Risk Improvement in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A Pivotal Study of Factors Associated with Carotid Intima-Media Thickness Reduction.Dermatology and therapy · 2023Article
- Impact of COVID-19 Pandemic on Hidradenitis Suppurativa Patients: a Cross-Sectional Study From Tertiary Referral Hospital.Dermatology practical & conceptual · 2022Article
- Clinical and Epidemiological Characteristics of Hidradenitis Suppurativa Patients with Paradoxical Psoriasiform Reactions following Treatment with Adalimumab.Skin appendage disorders · 2022Article
- Aquaporins Are One of the Critical Factors in the Disruption of the Skin Barrier in Inflammatory Skin Diseases.International journal of molecular sciences · 2022Review
- Article
- Mediterranean diet, lifestyle and quality of life in Sardinian patients affected with Hidradenitis suppurativa.Journal of public health research · 2021Article
- Cumulative Inflammation and HbA1c Levels Correlate with Increased Intima-Media Thickness in Patients with Severe Hidradenitis Suppurativa.Journal of clinical medicine · 2021Article
- Multidisciplinary Management of Adolescents with Hidradenitis Suppurativa - Series of Cases and Literature Review.Journal of multidisciplinary healthcare · 2021Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHidradenitis suppurativa (HS) is a chronic, inflammatory and recurrent skin disease. Different staging instruments have been suggested, but none has achieved universal acceptance. Despite the fact that Hurley staging is one of the most widely applied HS disease severity staging instruments, it has not been validated.
objectivesTo determine the inter- and intrarater reliability of the Hurley staging system.
methodsFifteen raters (five plastic surgeons, five general surgeons and five dermatologists) independently staged 30 photos of patients with HS according to Hurley staging at two time points. Reliability was assessed using kappa (&kgr;) statistics, and multivariable logistic regressions were used to determine independent risk factors for photos with discordant staging.
resultsInter-rater reliability was moderate for the three stages of HS [κ = 0·59, 95% confidence interval (CI) 0·48-0·70]. It was moderate for Hurley stage I (κ = 0·45, 95% CI 0·32-0·55) and stage II (κ = 0·51, 95% CI 0·31-0·71) and it was almost perfect for stage III (κ = 0·81, 95% CI 0·62-1·00). The intrarater reliability was substantial for all stages and all raters (κ = 0·65, 95% CI 0·58-0·72). For stage I it was moderate (κ = 0·50, 95% CI 0·38-0·62), for stage II it was substantial (κ = 0·62, 95% CI 0·51-0·73) and for stage III it was almost perfect (κ = 0·82, 95% CI 0·77-0·87). Hurley stages II and III were less likely to result in discordant staging than Hurley stage I (odds ratios 0·47, 95% CI 0·29-0·77 and 0·21, 95% CI 0·12-0·38, respectively). The mean time spent on staging a photo was 14 s.
conclusionsHurley staging is reliable for rapid severity assessment of HS, with moderate inter-rater and substantial intrarater reliability for all stages. It is best for assessing Hurley stage III HS, which is an indication for surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.